Movement disorder biotech Vima steps onto scene with $60M
Since Bernard Ravina's medical training in neurology in the '90s, there have been few new therapies that treat a movement disorder known as dystonia. "Nothing fundamentally has changed for these patients since then," the drug ...
Since Bernard Ravina's medical training in neurology in the '90s, there have been few new therapies that treat a movement disorder known as dystonia.
"Nothing fundamentally has changed for these patients since then," the drug ...
